Рак простаты

Study establishes new perioperative standard in prostate cancer - News-Medical

Study establishes new perioperative standard in prostate cancer News-Medical

Late-breaking: Novel alpha radiopharmaceutical therapy shows promising activity in phase 1 prostate cancer trial

Late-breaking: Novel alpha radiopharmaceutical therapy shows promising activity in phase 1 prostate cancer trial EurekAlert!

New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer - News-Medical

New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer News-Medical

New test could flag which men need aggressive prostate cancer treatment and which don't

New test could flag which men need aggressive prostate cancer treatment and which don't Fox News

Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and after prostate cancer surgery was further validated by a substudy…

New treatment approach shows promise in reducing prostate cancer spread

Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an international phase 3 trial.

FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer The ASCO Post

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death | Newswise

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death | Newswise Newswise

Johnson & Johnson Reports Phase 1 Prostate Cancer Drug Results at ESMO 2026

Johnson & Johnson Reports Phase 1 Prostate Cancer Drug Results at ESMO 2026 Yahoo

Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer

Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the…

New treatment approach shows promise in reducing prostate cancer spread

New treatment approach shows promise in reducing prostate cancer spread McGill University

ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence

ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence BioSpace

ESMO26: Combination therapies show promise in prostate cancer

ESMO26: Combination therapies show promise in prostate cancer Clinical Trials Arena

Fewer US men are diagnosed with low-risk prostate cancer, and more of them now choose surveillance over treatment

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis published in CANCER indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.